BioInvent International AB

BINV · Nasdaq Stockholm · Healthcare

22.90SEK +1.8%last day

Price as of 2 October 2026

The price over the past year, with dividends: −18.9%

Performance

1 month

−3.2%

1 year

−18.9%

3 years, per year

+11.0%

5 years, per year

−8.3%

Largest fall, 3 years

−76.6%

Below the peak now

−97.6%

Volatility, 1 year

54.2%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

4.6

Dividend yield

0.0%

Return on equity

−156.7%

Net margin

−154.0%

Market value

150 m USD

Quality, value and trend

Where BioInvent International stands against every Nordic stock today. 100 is best.

Quality93

Profitability and a sound balance sheet over time. Better than 93% of Nordic stocks.

Value3

The price measured against earnings, assets and cash flow. Better than 3% of Nordic stocks.

Trend36

The price development over the past year. Better than 36% of Nordic stocks.

Combined36

Quality, value and trend together. Better than 36% of Nordic stocks.

About BioInvent International

BioInvent International AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 110 employees.

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis